CooperVision Launches Biofinity® XR Contact Lenses
PLEASANTON, Calif., Oct. 21, 2013 /PRNewswire/ -- CooperVision, Inc. today announced the launch of its Biofinity® XR contact lens brand. This is an extension to its popular Biofinity (comfilcon A) silicone hydrogel technology, allowing practitioners to confidently fit a greater number of monthly replacement lens patients, including those with significant hyperopia and myopia.
(Photo: http://photos.prnewswire.com/prnh/20131021/SF00495-INFO)
Every day, countless people who suffer from severe near- and far-sightedness are faced with less than optimal choices to correct their vision. Thick glasses can create distortion and upend fashion sensibilities. Older contact lens materials limit "breathability," with less oxygen reaching the eye. And the latest high performance lenses have only covered a limited range of prescriptions.
The Biofinity XR lens is the first of its kind that combines high oxygen permeability with all-day comfort characteristics required for wearers with more demanding prescriptions. With Biofinity XR, more people can enjoy the benefits of modern contact lens material and design, helping them live life without the hassle of glasses.
"The availability of Biofinity XR gives eye care practitioners another reason to make it a monthly lens of choice, whether transitioning Proclear® wearers, upgrading from a competitive lens, or introducing a broader span of spectacle wearers to soft lenses," said Dr. Juan Carlos Aragon, senior vice president, Global Professional & Clinical Affairs, CooperVision. "The same outstanding vision, fit and comfort properties that the eye care community has come to expect from Biofinity are now available with Biofinity XR lenses."
Biofinity XR is the only extended range monthly contact lens brand with Aquaform® Technology. This technology makes the lens material highly breathable so more oxygen reaches the eyes, helping keep them clearer and whiter with less irritation. It also ensures that the lenses are naturally and uniformly wettable for smoothness and comfort, and maintains softness and flexibility for more gentle wear from the first day to the last.
Biofinity XR lenses are now available in powers from +8.50 to +15.00 (0.50 steps) and -12.50 to -20.00 (0.50 steps). The current Biofinity line continues to be available in +8.00 to -12.00 powers.
About CooperVision
CooperVision, a unit of The Cooper Companies, Inc. (NYSE: COO), is one of the world's leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About The Cooper Companies
The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE Euronext (NYSE: COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market-leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has over 8,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.
SOURCE CooperVision
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article